Lutris Pharma has concluded subject enrolment in its Phase II clinical trial of LUT014, a new B-Raf inhibitor designed for topical application to treat acneiform rash due to epidermal growth ...

Chemo rash is one of the most common side effects of cancer treatment. These rashes usually aren’t serious, but they can cause pain, itching, and other uncomfortable symptoms. Chemotherapy, also ...

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal cancer. News & Perspective Tools & Reference CME/CE More ...

In this study, Patel and her team found that treatment interruptions of anti-EGFR therapy due to acneiform rash occurred in 11 patients in the placebo group, four in the high-dose LUT014 group (P ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity, today announced that it has secured a $30 million ...

LUT014, a topical BRAF-inhibiting gel, may mitigate acneiform rash in patients receiving EGFR-targeted therapy for colorectal cancer, according to phase II clinical trial results presented by ...

Like many viral illnesses, COVID-19 can cause skin rashes, including hives. Last chance for Amazon Prime Day deals! Find deals on Apple, Tarte, more. IE 11 is not supported.

They have continued to see a lot of rashes, including poison ivy, viral rashes, sun-related rashes including phytophotodermatitis and polymorphous light eruption, hand-foot-mouth disease and impetigo.

In addition to causing skin rashes, COVID-19 infections can also exacerbate or trigger a recurrence of pre-existing skin issues you may have. That includes chronic skin conditions like psoriasis ...

An unexpected sign of seasonal allergies: Watch out for these 2 types of rashes According to Rachna Shah, the allergist and immunologist who heads Loyola Medicine's pollen count in Chicago, skin ...